- Clinical Trials
- February 2024
- 80 Pages
Global
From €1904EUR$2,000USD£1,628GBP
- Report
- January 2024
- 285 Pages
Global
From €9045EUR$9,500USD£7,731GBP
- Report
- March 2019
- 110 Pages
Global
From €3094EUR$3,250USD£2,645GBP
- Report
- March 2021
- 75 Pages
Global
€20946EUR$22,000USD£17,904GBP
- Report
- June 2018
- 15 Pages
Global
From €9521EUR$10,000USD£8,138GBP
- Clinical Trials
- January 2020
- 500 Pages
Global
From €2285EUR$2,400USD£1,953GBP
- Report
- September 2019
Global
From €5113EUR$5,370USD£4,370GBP
Duopa is a type of central nervous system (CNS) drug used to treat symptoms of Parkinson's disease. It is a combination of two drugs, carbidopa and levodopa, which are delivered directly into the small intestine via a pump. The drug is designed to provide a steady, continuous dose of the two drugs, which helps to reduce the "off" periods associated with Parkinson's disease. Duopa is a relatively new drug, having been approved by the U.S. Food and Drug Administration in 2015.
Duopa is a part of a larger market of CNS drugs, which includes medications used to treat a variety of neurological conditions, such as Alzheimer's disease, epilepsy, and multiple sclerosis. These drugs are typically used to reduce symptoms, improve quality of life, and slow the progression of the disease.
Companies in the Duopa market include AbbVie, Impax Laboratories, and Teva Pharmaceuticals. Show Less Read more